<DOC>
	<DOCNO>NCT00230763</DOCNO>
	<brief_summary>To determine predictive factor positive response latanoprost 0.005 % / timolol 0.5 % fix combination ( defined 10 % IOP reduction baseline ) , 12 week treatment ( age , sex , ethnic origin , patient 's medical history , family history OAG OHT , concomitant systemic treatment beta-blockers , etiology , IOP baseline , corneal thickness , compliance , adverse event ) .</brief_summary>
	<brief_title>Determination Of Predictive Factors Allowing To An Additional 10 % Reduction Of Intra-Ocular Pressure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Male female patient , Aged &gt; equal 18 year , Patient present OHT OAG IOP ï¿½ 21 mmHg , Patient currently treat ophthalmic betablockers monotherapy require change ophthalmic medication due insufficient response treatment , Patient currently treat receive within last month ophthalmic hypotensive agent betablocker , Patient present contraindication latanoprost timolol , Patient history asthma , obstructive bronchopneumopathy , sinusal bradycardia ( pulse rate &lt; 60 bpm ) , auriculoventricular block , cardiac insufficiency , Raynaud disease condition would preclude patient take prescribed medication , Patient know intolerance benzalkonium chloride excipient contain trial treatment ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>